Position in SVTR
Snapshot 2026-10-28- Startup SignalsRankedof 2,148new
- Life SciencesRankedof 221
- AI for ScienceTop 50%
- Drug DiscoveryRankedof 60
About
Atlas Bio builds an AI foundation model trained on roughly 2 million human RNA readouts to run in silico clinical trials that simulate patient-level drug efficacy and safety before Phase II, helping biotech and pharma de-risk development and move beyond animal testing.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 3
Founders / team· 2
Funding history
- 2026-10-27Seed$13M
Investors · Creandum, First Momentum Ventures, LEA PartnersSource · tech.eu ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Atlas Bio
Atlas Bio builds an AI foundation model trained on roughly 2 million human RNA readouts to run in silico clinical trials that simulate patient-level drug efficacy and safety before Phase II, helping biotech and pharma de-risk development and move beyond animal testing.
Seed · $13M · 2026-10
$13M
United States
BusinessLatest roundTotal raisedDate- Valinor
Models trained on multi-omics/longitudinal clinical data to predict clinical trial efficacy and stratify patients
Seed · $13M · 2025-12
$13M - Kerna Labs
AI/RNA foundation models to design and optimize mRNA sequences for next-generation mRNA therapies
$6M
$6M - Trially
AI to match, reach and recruit patients for clinical trials
Seed · $5M · 2025-09
$5M
China
BusinessLatest roundTotal raisedDate- Purui Intelligence
AI-driven platform for end-to-end clinical trial automation and results delivery.
Series A · $14M · 2026-06
$14M - Levinthal Biotech
AI protein design services, with the proprietary all-atom protein design platform Pallatom
Series A · $14M · 2025-12
$14M - LattixOrigin
Cross-scale human brain foundation model for drug target discovery in neurodegenerative diseases
Seed · 2026-10
—
Europe
BusinessLatest roundTotal raisedDate- Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M - Cyclana Bio
Tissue-level drug discovery model for treating endometriosis
Pre-Seed · $7M · 2025-10
$7M - Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M
Other / unspecified
BusinessLatest roundTotal raisedDate- 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Congruence
Computation-driven drugs for genetic diseases (including CGX-926)
Undisclosed · $32M · 2025-09
$32M - Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Y Combinator
39 Life Sciences deals in the last 24 months · 27 at a nearby stage · 1 in Switzerland
Request intro →Amino Collective
6 Life Sciences deals in the last 24 months · 5 at a nearby stage · 1 in Switzerland
Request intro →Connecticut Innovations
6 Life Sciences deals in the last 24 months · 3 at a nearby stage · 1 in Switzerland
Request intro →Speedinvest
5 Life Sciences deals in the last 24 months · 4 at a nearby stage · 1 in Switzerland
Request intro →GoHub Ventures
4 Life Sciences deals in the last 24 months · 4 at a nearby stage · 1 in Switzerland
Request intro →Nina Capital
4 Life Sciences deals in the last 24 months · 4 at a nearby stage · 1 in Switzerland
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.